Aura Biosciences (NASDAQ:AURA) Upgraded at Lifesci Capital

Lifesci Capital upgraded shares of Aura Biosciences (NASDAQ:AURA) to a strong-buy rating in a research note released on Friday morning,Zacks.com reports.

AURA has been the topic of a number of other research reports. Scotiabank increased their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the company a “sector outperform” rating in a research report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a research report on Friday, October 18th. BTIG Research increased their price objective on shares of Aura Biosciences from $21.00 to $24.00 and gave the company a “buy” rating in a research report on Friday, October 18th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Aura Biosciences in a research report on Thursday, November 14th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $23.00.

Aura Biosciences Stock Down 1.0 %

NASDAQ:AURA opened at $7.85 on Friday. The company’s 50 day moving average price is $8.28 and its 200-day moving average price is $8.90. Aura Biosciences has a 52 week low of $6.63 and a 52 week high of $12.38. The stock has a market cap of $392.11 million, a price-to-earnings ratio of -4.54 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. As a group, sell-side analysts anticipate that Aura Biosciences will post -1.66 earnings per share for the current year.

Insiders Place Their Bets

In other Aura Biosciences news, insider Janet Jill Hopkins sold 11,822 shares of Aura Biosciences stock in a transaction on Monday, November 18th. The shares were sold at an average price of $9.36, for a total value of $110,653.92. Following the completion of the transaction, the insider now directly owns 151,693 shares of the company’s stock, valued at $1,419,846.48. This trade represents a 7.23 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, insider Los Pinos Elisabet De sold 15,955 shares of the firm’s stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $7.67, for a total transaction of $122,374.85. Following the completion of the sale, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 28,778 shares of company stock worth $240,706. Company insiders own 5.40% of the company’s stock.

Institutional Investors Weigh In On Aura Biosciences

Institutional investors have recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. bought a new stake in Aura Biosciences during the 4th quarter valued at about $87,000. American Century Companies Inc. bought a new stake in Aura Biosciences during the 2nd quarter valued at about $119,000. SG Americas Securities LLC bought a new stake in Aura Biosciences during the 3rd quarter valued at about $169,000. JPMorgan Chase & Co. lifted its holdings in Aura Biosciences by 107.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock valued at $477,000 after buying an additional 27,718 shares in the last quarter. Finally, The Manufacturers Life Insurance Company lifted its holdings in Aura Biosciences by 14.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 64,452 shares of the company’s stock valued at $487,000 after buying an additional 8,194 shares in the last quarter. Institutional investors own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.